Background: Epidemiological studies suggest that lower total cholesterol (TC) may be associated with higher mortality. This study aimed to evaluate whether a decline in TC before death might account for the association of TC with mortality over age 80 years. Methods: Cohort study using primary care electronic health records of 99,758 participants aged 80-105 years from the UK Clinical Practice Research Datalink. Hazard ratios for all-cause mortality were adjusted for age, gender, frailty, comorbidity, blood pressure, and smoking. Fractional polynomial models were fitted to evaluate longitudinal trends in TC before death or end-of-study. Adjusted odds ratios were estimated using generalized estimating equations. Results: There were 63,630 women and 36,128 men, mean age 86 years, with 29,200 deaths. There were 41,164 treated with statins at cohort entry. Compared with TC values of 4.5-5.4 mmol/L, TC values <3.0 mmol/L were associated with higher mortality (statin treated hazard ratios 1.53, 95% confidence interval 1.43-1.64, p < .001; not treated, 1.41, 1.29-1.54, p < .001). A secular decline in TC values accelerated in the last 2 years of life. In the last quarter of follow-up, the adjusted odds of TC < 3.0 mmol/L for those who died, compared with surviving participants, were 3.33 (2.84-3.91, p < .001) for untreated and 1.88 (1.68-2.11, p < .001) for statin-treated participants. Conclusions: TC values show a terminal decline in the last years of life. Reverse causation may contribute to the association of lower TC with higher mortality in nonrandomized studies.
Background
A long-term decline in cardiovascular mortality has been associated with increasing longevity. People aged more than 80 years now represent the most rapidly increasing sector of the population in many highincome countries (1) . Cardiovascular diseases are now more frequent at older ages (2) and this poses important questions for cardiovascular disease prevention strategies for people aged 80 years and over. Hypertension, hypercholesterolemia, and smoking are recognized as the leading risk factors for cardiovascular diseases but, while smoking cessation may be advocated at any age, the role of antihypertensive and cholesterol-lowering therapy at advanced ages is more controversial.
The results of hypertension treatment trials in people aged more than 75 (3, 4) or 80 years (5) suggest that blood pressure-lowering may be associated with lower mortality and fewer cardiovascular events in these age groups. This evidence conflicts with the findings of nonrandomized epidemiological studies which generally show that lower blood pressure (BP) values are associated with higher mortality in older people (6, 7) . We recently analyzed systolic BP trajectories in people aged ≥80 years. These analyses revealed that systolic BP undergoes a "terminal decline" in the last 24 months of life (8) . This observation suggests that the association of lower BP with higher mortality in observational studies may be accounted for by reverse causation, if people with lower BP values are generally closer to the end of life (8) . A process of terminal decline has been suggested previously in studies of physical and cognitive functioning (9) (10) (11) (12) but the concept has not previously been applied in studies of cardiovascular risk factors.
There is strong evidence that cholesterol-lowering with statins is associated with reduced mortality and fewer cardiovascular events in primary and secondary prevention populations (13, 14) . The results of these clinical trials have led to increased prescribing of statins in the general population (15) , and statin prescribing is now spilling over into the oldest age groups (16) . However, Petersen et al. (17) concluded that there was no evidence from clinical trials that cholesterol-lowering treatment was associated with lower mortality in people aged more than 80 years. This lack of evidence is concerning because nonrandomized studies suggest that lower cholesterol levels might be associated with greater mortality in people aged more than 80 years (17) . In a review of 12 observational studies, Petersen et al. (17) found that the majority of cohort studies find that lower total cholesterol (TC) values are associated with higher all-cause mortality, and with higher cholesterol values being associated with lower mortality (18) . Data from some studies suggest a U-shaped, or reverse J-shaped association, of TC (17, 19) or low-density lipoprotein cholesterol with all-cause mortality in the elderly (20) . While some authors suggest that cholesterol may not be a risk factor for mortality in old age (20) , other commentators have emphasized the potential for reverse causation, if serious illness is associated with declining TC values (21) .
We hypothesized that serum TC values may show a terminal decline in old age, as was reported for systolic BP (8) . This study therefore aimed to analyze the association of TC level with mortality in people aged 80 years and older. We explored whether serum TC values undergo a terminal decline that might in part account for any associations of lower TC values with higher mortality. We investigated a large cohort of people aged 80 years and older, with stratified sampling to ensure representation of individuals up to 105 years of age.
Methods

Study Design
A population-based cohort study was conducted in the UK Clinical Practice Research Datalink (CPRD). The CPRD is the world's largest database of primary care electronic health records, covering approximately 7% of the UK family practices (22) . The CPRD population is considered to be representative of the UK population; the database includes comprehensive data for drug prescriptions and diagnoses recorded in primary care, which have been shown to be valid in many studies (22, 23) .
Study Participants
The sample was drawn from a complete listing of patients registered in CPRD as sampling frame. Stratified sampling by age and study year was employed to ensure adequate representation of older ages. Eligible participants were selected from patients aged at least 80 years old and registered with the UK Clinical Practice Research Datalink (CPRD) at any time between January 1, 2001 and the December 31, 2015. For each calendar year from 2001 to 2015, and for each single year of age from 80 to 105 years, up to a maximum of 1,000 patients were sampled from the population of patients registered during that year. The sampling procedure yielded fewer than 1,000 participants at older ages and some participants were sampled in more than 1 year. The sampling procedure yielded a total of 212,566 individual participants whose primary care electronic health records were analyzed for this study. We restricted the analysis to the first 5 years from cohort entry.
Study Measures
The main measures for the study were statin prescriptions, serum TC and all-cause mortality. Statins were considered as a single group based on all statins available for prescription between 2001 and 2015. Records for serum TC (mmol/L) were obtained from values recorded into primary care electronic records. The mean of all TC records during follow-up was included in the analysis using the categories <3.0, 3.0-3.4, 3.5-4.4, 4.5-5.4, and ≥5.5 mmol/L. All-cause mortality was analyzed using the date of death recorded into CPRD. Covariates were gender, 5-year age group, comorbidity and frailty category. Comorbidity was determined from analysis of Read medical codes, and where appropriate drug product codes, for diabetes mellitus, coronary heart disease, stroke, chronic obstructive pulmonary disease, dementia, digestive disorders, and musculoskeletal disorders as reported previously (24) . Frailty status was assessed using a previously published 36-item electronic Frailty Index (eFI) (25) . The eFI was devized from the cumulative deficit frailty model with the eFI score calculated by the presence or absence of individual deficits as a proportion of the total possible (26) . Quantitative traits, including BP, and polypharmacy were omitted from the eFI score for this study. Categories of fit, mild, moderate, and severe frailty were defined following Clegg et al. (25) . Participants' smoking status was evaluated using the most recent records into the categories "current smoker", "ex-smoker", "nonsmoker or not recorded." Systolic BP records were classified into the categories <110, 110-119, 120-139, 140-159, and ≥160 mm Hg, using the mean of all records during follow-up.
Analysis
The cohort was described by tabulating covariates by TC category and baseline statin treatment status. We evaluated the association of TC category with mortality in survival analyses. Since the distribution of TC differs substantially according to statin treatment status, participants were divided into those treated or not treated with statins at baseline. Participants were classified as statin treated if they received one or more statin prescriptions within the first 12 months of cohort entry. Kaplan-Meier curves were plotted to present the univariate association of TC category with all-cause mortality according to baseline statin treatment status. Cox proportional hazards models were fitted, separately for patients treated with statins and those not treated with statins. Univariate hazard ratios were estimated; then adjustment was made for age, gender, and frailty category; finally, comorbidities, systolic BP category, and smoking status were included. The proportional hazards assumption was evaluated using the Schoenfeld residuals. The analysis was conducted using the R program, using the "survival" and "survminer" packages (27) .
We evaluated the trajectory of TC over 5 years' follow-up, including all TC values recorded up to the date of death or end of study. For each month of follow-up, we estimated the mean TC value for each participant. Data for each participant month were classified as statin treated if participants had received a statin prescription in the previous 90 days. We used scatter plots to compare changes in mean TC values over time for participants who died by the end of the study and participants who remained alive. Data were smoothed with moving averages using three successive observations. We fitted second-order fractional polynomial (FP) models to evaluate trends in TC over time before death or end of study using mean TC values for each participant month as observations (28) . The month from 5 years before death to the end of study was included in FP models as a continuous predictor with values ranging from −60 to −1. FP models were adjusted for age, gender and frailty category. Models were fitted using the "mfp" package in the R program (28) . Predicted values and their 95% confidence intervals were estimated and overlaid on the scatterplot of empirical values. The relative odds of TC <3.0 mmol/L for deceased participants, compared with those who were alive at end of study, were estimated using the method of generalized estimating equations. Odds ratios were adjusted for age, gender and frailty category and clustering by participant.
Results
The initial cohort comprised 212,566 participants of whom 99,758 (47%) had one or more TC records within 5 years of entry to the study. A flowchart is shown in Supplementary Figure 1 . The remaining analyses include 99,758 participants including 36,128 (36%) men and 63,630 (64%) women aged 80 years or older. There were 58,594 patients not treated with statins and 41,164 patients treated with statins. There were 29,200 deaths during follow-up including 18,052 in nonusers of statins and 11,148 in statin users. Table 1 presents the characteristics of participants divided by serum TC level. TC decreased with age, but there was only 1 year difference in age between highest and lowest categories. In the highest TC category, 82% of participants were women, while only 34% of the lowest TC category were female. Lower TC values were associated with greater frailty, 55% of participants with TC less than 3.0 mmol/L had moderate or severe frailty, compared with 30% of those with TC ≥5.5 mmol/L. Participants with secondary prevention indications, including diabetes mellitus, coronary heart disease, and stroke were more highly represented in the lower TC categories, while trends were less marked or absent for other comorbidities. Low TC values were also strongly associated with lower systolic BP category and stronger association with previous smoking. Table 2 shows the distribution of covariates according to statin treatment status. As expected, statin-treated participants had generally lower TC values. Statin-treated participants also tended to be younger, were more frequently male, with greater levels of frailty and more frequently had comorbidities, especially secondary prevention indications including diabetes, coronary heart disease, and stroke. Figure 1 presents Kaplan-Meier curves by TC category for participants who were treated or not treated with statins. During the 5-year period of follow-up, there was a graded association of lower TC category with higher mortality. Participants with TC values <3.0 or 3.0-3.4 had higher mortality than participants with TC values of 4.5-5.4 or ≥5.5 mmol/L. This pattern of association was generally similar in statin-treated or untreated participants. Table 3 presents hazards ratios from the proportional hazards models. In univariate analyses, using TC values of 4.5-5.4 mmol/L as reference, there was a graded association of lower TC values with greater mortality. For participants with TC < 3.0 mmol/L, the relative hazard was approximately two times higher than reference for both statin treated and untreated participants. Adjustment for age, gender, and frailty category reduced hazard ratios, but the graded negative association of TC category with higher mortality remained. After further adjustment for comorbidities, systolic BP and smoking category, the adjusted hazard ratio for the lowest TC category was 1.41 (95% confidence interval 1.29-1.54) in participants not treated with statins and 1.53 (1.43-1.64) in participants treated with statins. In univariate analyses, there was evidence that the proportional Note: Figures are frequencies (column percent) . CHD = coronary heart disease; COPD = chronic obstructive pulmonary disease; DM = diabetes mellitus; MSK = musculoskeletal disorders.
hazards assumption for TC category did not hold either for statintreated (chi-square 33.8, p < .001) or untreated participants (chisquare 26.2, p < .001). For adjusted analyses in participants treated with statins, there was no evidence that the proportional hazards assumption was invalid, except for systolic BP category. For participants not treated with statins, there was evidence that the proportional hazards assumption did not hold for frailty category, systolic BP category, comorbidities of diabetes and cancer, with less strong evidence for nonproportionality with respect to TC category. The reported hazard ratios can be interpreted as the average effect over the duration of follow-up.
There were 262,518 participant months with TC values recorded. The median number of participants contributing data per month was 4,446 (range 1,934-6,480). There was a median of 2 months per participant with TC values recorded (range 1-34). Figure 2 presents a plot of TC values by month from 60 months to 1 month before death or end of study. Points represent the mean of TC values recorded in that month, smoothed as moving averages; shaded bands represent the 95% confidence limits for predicted values from the multiple fractional polynomial model. There is generally good agreement between empirical and predicted estimates. Data for participants treated with statins show generally lower TC values than for participants not treated with statins. In participants who did not die during follow-up, shown in blue, there is a declining secular trend in TC values over time but the data points appear to fit a linear trend. Participants who died during the 5-year study period show lower TC values throughout the period. However, data points fit a Table 1 presents the transformations and coefficients selected for the multiple FP models. Cubic terms were selected as best fit to data for participants who died, while square or inverse square terms were selected for participants who remained alive during the study period. In the last 3 months of life, in participants not treated with statins at baseline, 11.3% of women and 23.3% of men had TC values <3.0 mmol/L compared with 3.6% of women and 8.0% of men who did not die (Supplementary Table 2 and Supplementary Figure 2) . In the last quarter of follow-up, the adjusted relative odds of TC < 3.0 mmol/L for those who died, compared with surviving participants were 3.33 (2.84-3.91, p < .001) for untreated and 1.88 (1.68-2.11, p < .001) for statin treated participants.
Discussion
Main Findings
These nonrandomized data confirm an association of lower TC values with greater mortality in people aged more than 80 years. There was a strong univariate association of TC values <3.0 mmol/L or 3.0-3.4 mmol/L with increased mortality. This association was partly accounted for by confounding with frailty, comorbidity, BP, and smoking but even in adjusted analyses there was evidence that mortality might be 40%-50% higher in those with TC<3.0 mmol/L compared with 4.5-5.4 mmol/L as reference. We noted that there was evidence that the proportional hazards assumption did not hold in certain analyses. This might suggest that the significance of low TC values might vary over time before death. Longitudinal analysis of TC values in relation to date of death suggested that there is a terminal decline in TC values in the last 12-24 months of life, as we have reported previously for systolic BP (8) . This observation raises the possibility that the association between low TC and mortality might be accounted for in part by reverse causation because patients with lower TC values may be closer, on average, to the end-of-life. This might account for the lack of consistency between observational studies and randomized controlled trials in the association of TC with mortality. In randomized trials, participants in each trial will on average have a similar expected proximity to death, which may not be the case when comparison groups are assembled in observational studies. However, we caution that there are several potential explanations for the association of lower cholesterol with proximity to death with some writers associating elevated cholesterol with protection against infection (29) and improved immune defenses (30). Note: CI = Confidence interval; HR = Hazard ratio; N = Number of participants. 
Comparison With Other Studies
Petersen et al. (17) noted that most outcome trials of lipid-lowering therapy have been conducted in patients who are considerably younger than 80 years (31) . However, meta-analyses of data for participants aged ≥65 years suggest that statin therapy may reduce mortality when used for primary (32) or secondary prevention (33) . Petersen et al. (17) conducted a systematic review and found consistent evidence from nonrandomized studies that lower TC values are associated with higher mortality in people aged more than 80 years. The same pattern of association has been reported for low-density lipoprotein cholesterol values (20) , and for older people with type 2 diabetes mellitus (34) and heart failure (35) . Kalantar-Zadeh et al. (35) referred to the association of elevated cardiovascular risk factors with lower mortality as 'reverse epidemiology' and drew attention to the particular relevance of this phenomenon for very old people (36) . The mechanisms underlying this effect may include deteriorating organ functioning, diminishing nutritional status, as well as inflammatory processes (21, (35) (36) (37) . Higher TC values have also been associated with recovery from disability after illness (38) . The present data underline the importance of a longitudinal perspective because TC values may not track at consistent levels over time, but rather enter a phase of more accelerated decline some months before the end-of-life. This observation suggests reverse causation as a plausible explanation for the association of lower TC values with higher mortality. The observation also raises questions concerning the appropriateness of lipid-lowering therapy at the end-of-life.
Strengths and Limitations
The study had the strengths of data from a large cohort of individuals aged 80 years and over with stratified sampling ensuring representation up to the age of 105 years, drawing on a nationally representative data source in the United Kingdom. Mortality was comprehensively ascertained from dates of death recorded into primary care records. We classified patients' frailty level according to an established measure of frailty but this relied on medical diagnoses coded into electronic health records, consistent with a deficit accumulation model of frailty (25, 39) . This approach may not always be consistent with assessment of a frail phenotype characterized by weight loss, weakness, and low energy expenditure, though the two approaches are correlated at population level (40) . TC values were those recorded in clinical practice and we acknowledge that these suffer from several limitations. Fewer than half of all eligible participants had TC values recorded; cholesterol measurement methods were not standardized across the cohort; data for cholesterol subfractions were generally not available; and measurement occasions were those selected by clinicians. Decisions to perform cholesterol tests may have been associated with confounding by indication if investigations were ordered when patients presented with illness. Consequently, patients with nonmeasured cholesterol values might differ from those with values recorded, consistent with a "missing not at random" mechanism. The direction of any possible bias might be difficult to anticipate. We acknowledge that TC values were sparsely recorded during followup, with generally fewer than 5% of participants contributing data in each month of follow-up, with a median of two TC values per participant. Consequently, further prospective studies will be needed to confirm these observations. For survival analyses, we divided patients into two groups according to baseline statin treatment. We acknowledge that treatment inception and discontinuation may have occurred during follow-up (41) but the focus of our analysis was on TC levels and not on statin treatment. When TC trajectories were evaluated, statin utilization was evaluated for each period of followup. We acknowledge that there may be relevant variables that were not available for analysis. Patients' social status, social networks, and income may be associated with statin prescribing and with mortality but we did not have data available for analysis. We also acknowledge that the e-frailty index is based on a cumulative deficit model of frailty. It includes common comorbidities including diabetes, heart disease, stroke, and respiratory disease using distinct case definitions. Adjustment for comorbidity in addition to frailty could lead to problems of over-adjustment. However, comparison of estimates from models adjusted for frailty or frailty and comorbidity shows no difference in interpretation, though the generally lower estimates form the latter are consistent with reduced residual confounding.
Conclusions
These data from a large population-based cohort of adults aged from 80 to 105 years, confirm an association of low TC values with all-cause mortality. Longitudinal analysis of TC records reveals that TC values show a declining secular trend but there is evidence of an accelerated decline in TC values in the last 12-24 months of life, which is not observed in participants who do not die. The observation of a terminal decline in TC values suggests that reverse causation may in part account for the association of mortality with low TC in nonrandomized studies. These findings have relevance for both researchers and clinicians. These results draw the attention of researchers to the importance of studying longitudinal changes in physiological and pathophysiological measures in very old people. Such changes may be of prognostic importance and might indicate the need and potential for future intervention. In clinical contexts, these observations help to explain why randomized trial estimates may differ from those derived from observational studies, providing clinicians with reassurance that nonrandomized associations of lower TC with higher mortality might not be regarded as causal, but instead accounted for by reverse causation.
